Nalfurafine hydrochloride for the treatment of pruritus

Bibliography

• Pisoni RL, Wikstrom B, Elder SJ, Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2006;21:3495-505
   PubMed Web of Science ®Google Scholar
• Francos GC, Kauh YC, Gittlen SD, Elevated plasma histamine in chronic uremia. Effects of ketotifen on pruritus. Int J Dermatol 1991;30:884-9
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Greaves MW, Schmelz M. Itch. Lancet 2003;361:690-4
   PubMed Web of Science ®Google Scholar
• Mathur VS, Lindberg J, Germain M, A longitudinal study of uremic pruritus in hemodialysis patients. Clin J Am Soc Nephrol 2010;5:1410-19
   PubMed Web of Science ®Google Scholar
• Gunal AI, Ozalp G, Yoldas TK, Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 2004;19:3137-9
   PubMed Web of Science ®Google Scholar
• Breneman DL, Cardone JS, Blumsack RF, Topical capsaicin for treatment of hemodialysis-related pruritus. J Am Acad Dermatol 1992;26:91-4
   PubMed Web of Science ®Google Scholar
• Tarng DC, Cho YL, Liu HN, Huang TP. Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Nephron 1996;72:617-22
   PubMed Web of Science ®Google Scholar
• Gilchrest BA, Rowe JW, Brown RS, Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Ann Intern Med 1979;91:17-21
   PubMed Web of Science ®Google Scholar
• Silva SR, Viana PC, Lugon NV, Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron 1994;67:270-3
   PubMed Web of Science ®Google Scholar
• Szepietowski JC, Szepietowski T, Reich A. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study. Acta Dermatovenerol Croat 2005;13:97-103
   PubMedGoogle Scholar
• Pauli-Magnus C, Klumpp S, Alscher DM, Short-term efficacy of tacrolimus ointment in severe uremic pruritus. Perit Dial Int 2000;20:802-3
   PubMed Web of Science ®Google Scholar
• Kuypers DR, Claes K, Evenepoel P, A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. Nephrol Dial Transplant 2004;19:1895-901
   PubMed Web of Science ®Google Scholar
• Guideline Subcommittee ‘Chronic Pruritus'. EDF-Guidelines for Chronic Pruritus. European Dermatology Forum, Zurich; 2011
   Google Scholar
• Manenti L, Vaglio A. Gabapentin for uraemic pruritus. Nephrol Dial Transplant 2005;20:1278-9
   PubMed Web of Science ®Google Scholar
• Gaspari A. Thalidomide neurotoxicity in dermatological patients: the next ‘STEP'. J Invest Dermatol 2002;119:987-8
   PubMed Web of Science ®Google Scholar
• Morton CA, Lafferty M, Hau C, Pruritus and skin hydration during dialysis. Nephrol Dial Transplant 1996;11:2031-6
   PubMed Web of Science ®Google Scholar
• Zakrzewska-Pniewska B, Jedras M. Is pruritus in chronic uremic patients related to peripheral somatic and autonomic neuropathy? Study by R-R interval variation test (RRIV) and by sympathetic skin response (SSR). Neurophysiol Clin 2001;31:181-93
   PubMed Web of Science ®Google Scholar
• Johansson O, Hilliges M, Stahle-Backdahl M. Intraepidermal neuron-specific enolase (NSE)-immunoreactive nerve fibres: evidence for sprouting in uremic patients on maintenance hemodialysis. Neurosci Lett 1989;99:281-6
   PubMed Web of Science ®Google Scholar
• Peer G, Kivity S, Agami O, Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 1996;348:1552-4
   PubMed Web of Science ®Google Scholar
• Urbonas A, Schwartz RA, Szepietowski JC. Uremic pruritus: an update. Am J Nephrol 2001;21:343-50
   PubMed Web of Science ®Google Scholar
• Fusaro M, Munaretto G, Spinello M, Gallieni M. Regression of uraemic pruritus by cyclosporin treatment in a haemodialysis patient. Nephrol Dial Transplant 2004;19:1338-9
   PubMed Web of Science ®Google Scholar
• Mettang T, Pauli-Magnus C, Alscher DM. Uraemic pruritus: new perspectives and insights from recent trials. Nephrol Dial Transplant 2002;17:1558-63
   PubMed Web of Science ®Google Scholar
• Kuypers DR. Skin problems in chronic kidney disease. Nat Clin Pract Nephrol 2009;5:157-70
   PubMedGoogle Scholar
• Kimmel M, Alscher DM, Dunst R, The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant 2006;21:749-55
   PubMed Web of Science ®Google Scholar
• Kumagai H, Saruta T, Matsukawa S, Utsumi J. Prospects for a novel kappa-opioid receptor agonist, TRK-820, in uremic pruritus. In: Yosipovitch G, Greaves MW, editors. Itch/basic mechanisms and therapy. Marcel Dekker, New York; 2004. p. 279-86
   Google Scholar
• Pan ZZ. Mu-opposing actions of the kappa-opioid receptor. Trends Pharmacol Sci 1998;19:94-8
   PubMed Web of Science ®Google Scholar
• Kumagai H, Ebata T, Takamori K, Effect of a novel kappa-receptor agonist, wurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 2010;25:1251-7
   PubMed Web of Science ®Google Scholar
• Japan Dialysis Medical Science Association Statistics Investigation Committee. An overview of regular dialysis treatment in Japan as of Dec. 31, 2010. Japanese Society for Dialysis Therapy, Tokyo; 2011
   Google Scholar
• Pauli-Magnus C, Mikus G, Alscher DM, Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol 2000;11:514-19
   PubMed Web of Science ®Google Scholar
• Legroux-Crespel E, Cledes J, Misery L. A comparative study on the effects of naltrexone and loratadine on uremic pruritus. Dermatology 2004;208:326-30
   PubMed Web of Science ®Google Scholar
• Phan NQ, Bernhard JD, Luger TA, Stander S. Antipruritic treatment with systemic mu-opioid receptor antagonists: a review. J Am Acad Dermatol 2010;63:680-8
   PubMed Web of Science ®Google Scholar
• Szmuszkovicz J, Von Voigtlander PF. Benzeneacetamide amines: structurally novel non-m mu opioids. J Med Chem 1982;25:1125-6
   PubMed Web of Science ®Google Scholar
• Millan MJ. Kappa-opioid receptors and analgesia. Trends Pharmacol Sci 1990;11:70-6
   PubMed Web of Science ®Google Scholar
• Nagase H, Hayakawa J, Kawamura K, Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan. Chem Pharm Bull (Tokyo) 1998;46:366-9
   PubMed Web of Science ®Google Scholar
• Portoghese AS, Lipkowski AW, Takemori AE. Bimorphinans as highly selective, potent kappa opioid receptor antagonists. J Med Chem 1987;30:238-9
   PubMed Web of Science ®Google Scholar
• Portoghese PS, Nagase H, Lipkowski AW, Binaltorphimine-related bivalent ligands and their kappa opioid receptor antagonist selectivity. J Med Chem 1988;31:836-41
   PubMed Web of Science ®Google Scholar
• Mori T, Nomura M, Nagase H, Effects of a newly synthesized kappa-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats. Psychopharmacology (Berl) 2002;161:17-22
   PubMed Web of Science ®Google Scholar
• Nagase H. Design and synthesis of delta and kappa opioid receptor agonists and their pharmacologies. Anesth 21 Century 2008;10:1941-52
   Google Scholar
• Togashi Y, Umeuchi H, Okano K, Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol 2002;435:259-64
   PubMed Web of Science ®Google Scholar
• Wakasa Y, Fujiwara A, Umeuchi H, Inhibitory effects of TRK-820 on systemic skin scratching induced by morphine in rhesus monkeys. Life Sci 2004;75:2947-57
   PubMed Web of Science ®Google Scholar
• Seki T, Awamura S, Kimura C, Pharmacological properties of TRK-820 on cloned mu-, delta- and kappa-opioid receptors and nociceptin receptor. Eur J Pharmacol 1999;376:159-67
   PubMed Web of Science ®Google Scholar
• Nakao K, Ikeda K, Kurokawa T, Effect of TRK-820, a selective kappa opioid receptor agonist, on scratching behavior in an animal model of atopic dermatitis. Nihon Shinkei Seishin Yakurigaku Zasshi 2008;28:75-83
   PubMedGoogle Scholar
• Nakao K, Mochizuki H. Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients. Drugs Today (Barc) 2009;45:323-9
   PubMed Web of Science ®Google Scholar
• Ndoye A, Buchli R, Greenberg B, Identification and mapping of keratinocyte muscarinic acetylcholine receptor subtypes in human epidermis. J Invest Dermatol 1998;111:410-16
   PubMed Web of Science ®Google Scholar
• Umeuchi H, Togashi Y, Honda T, Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system. Eur J Pharmacol 2003;477:29-35
   PubMed Web of Science ®Google Scholar
• Nakao K, Ando A, Hirakata M, The pharmacological and clinical profiles of nalfurafine hydrochloride (Remitch® capsules 2.5 microgram), a new therapeutic agent for the treatment of uremic pruritus in hemodialysis patients. Folia Pharmacol Jpn 2010;135:205-14
   PubMedGoogle Scholar
• Wikstrom B, Gellert R, Ladefoged SD, Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 2005;16:3742-7
   PubMed Web of Science ®Google Scholar
• Araujo SM, de Bruin VM, Daher ED, Risk factors for depressive symptoms in a large population on chronic hemodialysis. Int Urol Nephrol 2011; publiched online 22 july 201; doi 10.1007/s11255-011-0032-9
   Web of Science ®Google Scholar
• Inui S, Shirakawa Y, Itami S. Effect of nalfurafine hydrochloride on pruritus and anxiety level in hemodialysis patients. J Dermatol 2011; published online 5 December 2011; doi: 10.1111/j.1346-8138.2011.01442.x.
   Web of Science ®Google Scholar
• Bigliardi PL, Bigliardi-Qi M, Buechner S, Rufli T. Expression of mu-opiate receptor in human epidermis and keratinocytes. J Invest Dermatol 1998;111:297-301
   PubMed Web of Science ®Google Scholar
• Bigliardi PL, Stammer H, Jost G, Treatment of pruritus with topically applied opiate receptor antagonist. J Am Acad Dermatol 2007;56:979-88
   PubMed Web of Science ®Google Scholar
• Stander S, Gunzer M, Metze D, Localization of mu-opioid receptor 1A on sensory nerve fibers in human skin. Regul Pept 2002;110:75-83
   PubMedGoogle Scholar
• Bigliardi-Qi M, Sumanovski LT, Buchner S, Mu-opiate receptor and Beta-endorphin expression in nerve endings and keratinocytes in human skin. Dermatology 2004;209:183-9
   PubMed Web of Science ®Google Scholar
• Tominaga M, Ogawa H, Takamori K. Possible roles of epidermal opioid systems in pruritus of atopic dermatitis. J Invest Dermatol 2007;127:2228-35
   PubMed Web of Science ®Google Scholar
• Kurban MS, Boueiz A, Kibbi AG. Cutaneous manifestations of chronic kidney disease. Clin Dermatol 2008;26:255-64
   PubMed Web of Science ®Google Scholar